Feinsod Matthew has filed 5 insider transactions across 1 company since March 2025.
Most recent transaction: a grant/award of 135000 shares of Kalaris Therapeutics, Inc. ($KLRS) on March 19, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 19, 2026 | Kalaris Therapeutics, Inc. | $KLRS | Feinsod Matthew | Chief Medical Officer | A | Stock Option (Right to Buy) | 135000 | $0.00 | 135,000.0000 | 18,702,418 | 9999.99% | 0.72% |
| April 10, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Feinsod Matthew | Chief Medical Officer | A | Stock Option (Right to Buy) | 70551 | $0.00 | 70,551.0000 | 5,043,357 | 9999.99% | 1.40% |
| April 10, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Feinsod Matthew | Chief Medical Officer | A | Stock Option (Right to Buy) | 101000 | $0.00 | 101,000.0000 | 5,043,357 | 9999.99% | 2.00% |
| March 18, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Feinsod Matthew | Chief Medical Officer | A | Common Stock | 4030 | $0.00 | 4,030.0000 | 5,043,357 | 9999.99% | 0.08% |
| March 18, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Feinsod Matthew | Chief Medical Officer | A | Stock Option (right to buy) | 28224 | $0.00 | 28,224.0000 | 5,043,357 | 9999.99% | 0.56% |